Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2022 Jan;62(1):106-108.
doi: 10.1111/head.14244. Epub 2021 Dec 7.

Combination CGRP monoclonal antibody and onabotulinumtoxinA treatment for preventive treatment in chronic migraine

Jessica Ailani  1 , Andrew M Blumenfeld  2
Affiliations
Comment

Combination CGRP monoclonal antibody and onabotulinumtoxinA treatment for preventive treatment in chronic migraine

Jessica Ailani et al. Headache. 2022 Jan.
No abstract available

Keywords: botulinum toxins type A; episodic migraine; headache; prevention.

PubMed Disclaimer

Conflict of interest statement

Jessica Ailani, MD, has served as a consultant for AbbVie, Amgen, Axsome, Aeon, CtrlM, Eli Lilly and Company, Lundbeck, Impel, Satsuma, Theranica, Teva, GlaxoSmithKline, and Nesos; has served as a speaker for Allergan/AbbVie, Amgen, Eli Lilly and Company, Lundbeck, and Teva; has received honoraria from Medscape; and has provided editorial services to Current Pain and Headache Reports, NeurologyLive, and SELF magazine. Her institute has received clinical trial support from Allergan/AbbVie, the American Migraine Foundation, Biohaven, Eli Lilly and Company, Satsuma, and Zosano. Andrew M. Blumenfeld, MD, has served on advisory boards for AbbVie, Aeon, Amgen, Alder, Axsome, Biohaven, Revance, Lundbeck, Novartis, Teva, Supernus, Promius, Egalet, Eli Lilly and Company, and Zosano; and has received funding for speaking from AbbVie, Amgen, Pernix, Supernus, Depomed, Avanir, Promius, Teva, and Eli Lilly and Company.

Comment on

References

    1. Pellesi L, Do TP, Ashina H, Ashina M, Burstein R. Dual therapy with anti‐CGRP monoclonal antibodies and botulinum toxin for migraine prevention: is there a rationale? Headache. 2020;60:1056‐1065. - PubMed
    1. American Headache Society . The American Headache Society position statement on integrating new migraine treatments into clinical practice. Headache. 2019;59:1‐18. - PubMed
    1. Rothrock JF, Adams AM, Lipton RB, et al. FORWARD study: evaluating the comparative effectiveness of onabotulinumtoxinA and topiramate for headache prevention in adults with chronic migraine. Headache. 2019;59:1700‐1713. - PMC - PubMed
    1. Tepper S, Ashina M, Reuter U, et al. Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double‐blind, placebo‐controlled phase 2 trial. Lancet Neurol. 2017;16:425‐434. - PubMed
    1. Ailani J, Burch RC, Robbins MS. The American Headache Society consensus statement: update on integrating new migraine treatments into clinical practice. Headache. 2021;61:1021‐1039. - PubMed

MeSH terms

Substances